| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NMETH.4027 |
| P698 | PubMed publication ID | 27723754 |
| P50 | author | Xing Chang | Q57035048 |
| P2093 | author name string | Yunqing Ma | |
| Yan Song | |||
| Zhenchao Zhang | |||
| Jiayuan Zhang | |||
| Weijie Yin | |||
| P2860 | cites work | Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation | Q36403602 |
| Molecular mechanisms of antibody somatic hypermutation. | Q36747477 | ||
| The biochemistry of somatic hypermutation | Q37096080 | ||
| Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. | Q38874534 | ||
| Mutations occur in the Ig Smu region but rarely in Sgamma regions prior to class switch recombination | Q40240123 | ||
| C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. | Q40627624 | ||
| Fine-structure analysis of activation-induced deaminase accessibility to class switch region R-loops | Q41098123 | ||
| Mutational pattern and frequency of induced nucleotide changes in mouse ENU mutagenesis | Q41835481 | ||
| Analyzing CRISPR genome-editing experiments with CRISPResso | Q42551389 | ||
| A system for the continuous directed evolution of biomolecules | Q42723725 | ||
| AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts | Q42813803 | ||
| Separate domains of AID are required for somatic hypermutation and class-switch recombination | Q42828095 | ||
| High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance | Q43966244 | ||
| Man-made cell-like compartments for molecular evolution | Q47857062 | ||
| Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands | Q48009144 | ||
| Estimate of the mutation rate per nucleotide in humans | Q24548130 | ||
| Cas9 as a versatile tool for engineering biology | Q24564294 | ||
| Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia | Q24599829 | ||
| Engineering of TEV protease variants by yeast ER sequestration screening (YESS) of combinatorial libraries | Q24630061 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Structural basis for the autoinhibition of c-Abl tyrosine kinase | Q27640773 | ||
| Crystal structure of human uracil-DNA glycosylase in complex with a protein inhibitor: protein mimicry of DNA | Q27729896 | ||
| Activation-induced cytidine deaminase turns on somatic hypermutation in hybridomas | Q28217205 | ||
| Development and applications of CRISPR-Cas9 for genome engineering | Q28241526 | ||
| Genome editing. The new frontier of genome engineering with CRISPR-Cas9 | Q28252298 | ||
| CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea | Q29614740 | ||
| Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
| Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements | Q29615788 | ||
| Genetic screens in human cells using the CRISPR-Cas9 system | Q29617411 | ||
| Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification | Q29618788 | ||
| CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. | Q33985645 | ||
| Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage | Q34046684 | ||
| Saturation editing of genomic regions by multiplex homology-directed repair | Q34143368 | ||
| Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. | Q34147986 | ||
| Structural basis for CRISPR RNA-guided DNA recognition by Cascade | Q34175461 | ||
| Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. | Q34175760 | ||
| R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells | Q34188845 | ||
| Mechanisms and implications of imatinib resistance mutations in BCR-ABL. | Q34283884 | ||
| A Heritable Recombination system for synthetic Darwinian evolution in yeast | Q34588001 | ||
| Evolution of enzyme catalysts caged in biomimetic gel-shell beads | Q35229077 | ||
| Strategies to overcome resistance to targeted protein kinase inhibitors | Q35968384 | ||
| Direct Identification of Hundreds of Expression-Modulating Variants using a Multiplexed Reporter Assay | Q36040300 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1029-1035 | |
| P577 | publication date | 2016-10-10 | |
| P1433 | published in | Nature Methods | Q680640 |
| P1476 | title | Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells | |
| P478 | volume | 13 |
| Q89503064 | A Processive Protein Chimera Introduces Mutations across Defined DNA Regions In Vivo |
| Q89128867 | A Rapid and Precise Mutation-Activated Fluorescence Reporter for Analyzing Acute Mutagenesis Frequency |
| Q52347620 | A Rice Dual-localized Pentatricopeptide Repeat Protein is involved in Organellar RNA Editing together with OsMORFs. |
| Q45981156 | A Single-Chain Photoswitchable CRISPR-Cas9 Architecture for Light-Inducible Gene Editing and Transcription. |
| Q57468202 | Acceleration of cancer science with genome editing and related technologies |
| Q90243529 | Adenine base editors catalyze cytosine conversions in human cells |
| Q47281660 | Am I ready for CRISPR? A user's guide to genetic screens |
| Q64376468 | An Adaptable Platform for Directed Evolution in Human Cells |
| Q60927165 | BE-FLARE: a fluorescent reporter of base editing activity reveals editing characteristics of APOBEC3A and APOBEC3B |
| Q89014293 | BE-PLUS: a new base editing tool with broadened editing window and enhanced fidelity |
| Q92067599 | BEAT: A Python Program to Quantify Base Editing from Sanger Sequencing |
| Q94469372 | BEON: A Functional Fluorescence Reporter for Quantification and Enrichment of Adenine Base-Editing Activity |
| Q92309492 | Base editing in crops: current advances, limitations and future implications |
| Q100737258 | Base editing: advances and therapeutic opportunities |
| Q57464865 | Base editing: precision chemistry on the genome and transcriptome of living cells |
| Q58120494 | Blossom of CRISPR technologies and applications in disease treatment |
| Q64059789 | CRISPR Cpf1 proteins: structure, function and implications for genome editing |
| Q99584450 | CRISPR base editing and prime editing: DSB and template-free editing systems for bacteria and plants |
| Q55172646 | CRISPR base editors: genome editing without double-stranded breaks. |
| Q64079272 | CRISPR directed evolution of the spliceosome for resistance to splicing inhibitors |
| Q64079276 | CRISPR enables directed evolution in plants |
| Q47909228 | CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia |
| Q30275336 | CRISPR-Cas9-AID base editor is a powerful gain-of-function screening tool |
| Q57059868 | CRISPR-Cas9-mediated base-editing screening in mice identifies DND1 amino acids that are critical for primordial germ cell development |
| Q48112768 | CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy |
| Q46309410 | CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons |
| Q58779052 | CRISPR-SKIP: programmable gene splicing with single base editors |
| Q45060692 | CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. |
| Q56889333 | CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window |
| Q46190066 | CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine |
| Q47990831 | Cas9, Cpf1 and C2c1/2/3-What's next? |
| Q52427338 | Choosing CRISPR-based screens in cancer. |
| Q36258853 | Creation of Novel Protein Variants with CRISPR/Cas9-Mediated Mutagenesis: Turning a Screening By-Product into a Discovery Tool |
| Q91692625 | Dead Cas Systems: Types, Principles, and Applications |
| Q55348060 | Directed evolution of multiple genomic loci allows the prediction of antibiotic resistance. |
| Q90299396 | EditR: A Method to Quantify Base Editing from Sanger Sequencing |
| Q41285231 | Editing base in mouse model |
| Q88985366 | Editing plant genes one base at a time |
| Q45996655 | Editing the Genome Without Double-Stranded DNA Breaks. |
| Q42343182 | Effective gene editing by high-fidelity base editor 2 in mouse zygotes |
| Q61800376 | Engineer chimeric Cas9 to expand PAM recognition based on evolutionary information |
| Q99727671 | Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editing |
| Q61124564 | Engineering of high-precision base editors for site-specific single nucleotide replacement |
| Q89637844 | Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors |
| Q91315021 | EvolvR-ing to targeted mutagenesis |
| Q92534404 | Expanding C-T base editing toolkit with diversified cytidine deaminases |
| Q92609296 | Forward genetic approach for behavioral neuroscience using animal models |
| Q57025328 | Functional Genetic Variants Revealed by Massively Parallel Precise Genome Editing |
| Q89360903 | Functional Genomics via CRISPR-Cas |
| Q36306820 | Functional interrogation of non-coding DNA through CRISPR genome editing |
| Q39201399 | Functional variomics and network perturbation: connecting genotype to phenotype in cancer. |
| Q101040781 | Genetic Modulation of RNA Splicing with a CRISPR-Guided Cytidine Deaminase |
| Q52429681 | Genome Editing: Past, Present, and Future. |
| Q45875285 | Genome Editing: The Recent History and Perspective in Cardiovascular Diseases |
| Q96641394 | Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors |
| Q33628093 | Genome engineering of stem cell organoids for disease modeling |
| Q89993737 | Genome, Epigenome, and Transcriptome Editing via Chemical Modification of Nucleobases in Living Cells |
| Q38842681 | Genome-wide target specificities of CRISPR RNA-guided programmable deaminases |
| Q49917892 | Harnessing natural DNA modifying activities for editing of the genome and epigenome. |
| Q47594697 | High-Throughput Approaches to Pinpoint Function within the Noncoding Genome |
| Q91624025 | Highly Efficient Base Editing in Viral Genome Based on Bacterial Artificial Chromosome Using a Cas9-Cytidine Deaminase Fused Protein |
| Q50986337 | Highly efficient RNA-guided base editing in mouse embryos. |
| Q55646260 | Highly efficient RNA-guided base editing in rabbit. |
| Q57146141 | Highly efficient base editing in bacteria using a Cas9-cytidine deaminase fusion |
| Q42651117 | Highly efficient base editing in human tripronuclear zygotes |
| Q45873745 | Immunity to CRISPR Cas9 and Cas12a therapeutics |
| Q41562658 | Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. |
| Q33786397 | Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. |
| Q45870138 | In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing |
| Q64056410 | In vivo continuous evolution of metabolic pathways for chemical production |
| Q92488793 | In vivo ways to unveil off-targets |
| Q94563242 | Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain |
| Q41960134 | Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions |
| Q89864978 | MagnEdit-interacting factors that recruit DNA-editing enzymes to single base targets |
| Q61450646 | Methodologies for Improving HDR Efficiency |
| Q47594709 | Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes |
| Q92730750 | Modern Trends in Plant Genome Editing: An Inclusive Review of the CRISPR/Cas9 Toolbox |
| Q47387337 | Modern methods for laboratory diversification of biomolecules |
| Q58776633 | Mouse models in the era of large human tumour sequencing studies |
| Q97636545 | New base editors change C to A in bacteria and C to G in mammalian cells |
| Q89403748 | Optimized base editors enable efficient editing in cells, organoids and mice |
| Q92017374 | PASTMUS: mapping functional elements at single amino acid resolution in human cells |
| Q92093205 | Perturbing proteomes at single residue resolution using base editing |
| Q50453614 | Precise base editing in rice, wheat and maize with a Cas9-cytidine deaminase fusion |
| Q52430510 | Precision genome engineering through adenine and cytosine base editing. |
| Q90682616 | Probing pathways of adaptation with continuous evolution |
| Q91904925 | Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs |
| Q52430904 | Programmable Single and Multiplex Base-Editing in Bombyx mori Using RNA-Guided Cytidine Deaminases. |
| Q38649381 | Progress and prospects in plant genome editing. |
| Q37639765 | Progress in Genome Editing Technology and Its Application in Plants |
| Q36288331 | Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. |
| Q98196784 | Recent advances of genome editing and related technologies in China |
| Q92982207 | Scalable, Continuous Evolution of Genes at Mutation Rates above Genomic Error Thresholds |
| Q64084610 | Screening of CRISPR/Cas base editors to target the AMD high-risk Y402H complement factor H variant |
| Q91522635 | Single-cell analysis of a mutant library generated using CRISPR-guided deaminase in human melanoma cells |
| Q92313555 | Single-nucleotide editing: From principle, optimization to application |
| Q90344708 | Synthetic Biology Speeds Up Drug Target Discovery |
| Q92826707 | Synthetic evolution |
| Q48103480 | Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes |
| Q47128146 | Targeted Base Editing via RNA-Guided Cytidine Deaminases in Xenopus laevis Embryos. |
| Q92610724 | Targeted, random mutagenesis of plant genes with dual cytosine and adenine base editors |
| Q91451483 | Targeting specificity of APOBEC-based cytosine base editor in human iPSCs determined by whole genome sequencing |
| Q55233775 | The CRISPR tool kit for genome editing and beyond. |
| Q98779241 | The Development and Application of a Base Editor in Biomedicine |
| Q93055710 | The evolving CRISPR technology |
| Q92419599 | The next generation of CRISPR-Cas technologies and applications |
| Q89617956 | The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations |
| Q39333650 | Treatment of Dyslipidemia Using CRISPR/Cas9 Genome Editing |
| Q99561776 | Unbiased investigation of specificities of prime editing systems in human cells |
| Q48540221 | Updated summary of genome editing technology in human cultured cells linked to human genetics studies |
| Q92765016 | beditor: A Computational Workflow for Designing Libraries of Guide RNAs for CRISPR-Mediated Base Editing |
| Q100407541 | enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9 |
Search more.